A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia

NCT01263704 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphocytic Leukemia, Chronic

Interventions

DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Rituximab

Sponsor

Hoffmann-La Roche